These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 690689)

  • 1. Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases.
    MacKay AR; Sang U H; Weinstein PR
    J Neurosurg; 1978 Oct; 49(4):597-601. PubMed ID: 690689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.
    Galassi G; Gibertoni M; Corradini L; Colombo A
    Ital J Neurol Sci; 1983 Dec; 4(4):489-92. PubMed ID: 6674249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy. Case report.
    Brodkin HM
    J Neurosurg; 1980 Nov; 53(5):690-2. PubMed ID: 7431078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epsilon-aminocaproic acid myopathy. Report of a case and literature review.
    Vanneste JA; van Wijngaarden GK
    Eur Neurol; 1982; 21(4):242-8. PubMed ID: 7117311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myopathy induced by epsilon-aminocaproic acid. Case report.
    Brown JA; Wollmann RL; Mullan S
    J Neurosurg; 1982 Jul; 57(1):130-4. PubMed ID: 7086489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rhabdomyolysis during treatment with epsilon-aminocaproic acid.
    Britt CW; Light RR; Peters BH; Schochet SS
    Arch Neurol; 1980 Mar; 37(3):187-8. PubMed ID: 7356431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epsilon aminocaproic acid (EACA) myopathy.
    Lane RJ; McLelland NJ; Martin AM; Mastaglia FL
    Postgrad Med J; 1979; 55(642):282-5. PubMed ID: 471867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epsilon-aminocaproic acid-induced myopathy. A case report.
    Morris CD; Jacobs P; Berman PA; Rutherfoord GS
    S Afr Med J; 1983 Sep; 64(10):363-6. PubMed ID: 6612533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis. Case report.
    Tubbs RR; Benjamin SP; Dohn DE
    J Neurosurg; 1979 Jul; 51(1):94-7. PubMed ID: 448423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative determination of plasma fibrinolytic activity in patients with ruptured intracranial aneurysms who are receiving epsilon-aminocaproic acid: relationship of possible complications of therapy to the degree of fibrinolytic inhibition.
    Burchiel KJ; Hoffman JM; Bakay RA
    Neurosurgery; 1984 Jan; 14(1):57-63. PubMed ID: 6537999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myonecrosis as a complication of the use of epsilon amino-caproic acid: a case report and review of the literature.
    Kane MJ; Silverman LR; Rand JH; Paciucci PA; Holland JF
    Am J Med; 1988 Dec; 85(6):861-3. PubMed ID: 3057905
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute renal failure and myopathy after treatment with aminocaproic acid.
    Biswas CK; Milligan DA; Agte SD; Kenward DH; Tilley PJ
    Br Med J; 1980 Jul; 281(6233):115-6. PubMed ID: 7427206
    [No Abstract]   [Full Text] [Related]  

  • 13. Epsilon-aminocaproic acid and recurrent subarachnoid hemorrhage: a clinical trial.
    Shucart WA; Hussain SK; Cooper PR
    J Neurosurg; 1980 Jul; 53(1):28-31. PubMed ID: 7411206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebral thrombosis associated with Amicar therapy.
    Hoffman EP; Koo AH
    Radiology; 1979 Jun; 131(3):687-9. PubMed ID: 441374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous subarachnoid hemorrhage complicated by communicating hydrocephalus: epsilon amino caproic acid as a possible predisposing factor.
    Park BE
    Surg Neurol; 1979 Jan; 11(1):73-80. PubMed ID: 451853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage.
    Starke RM; Kim GH; Fernandez A; Komotar RJ; Hickman ZL; Otten ML; Ducruet AF; Kellner CP; Hahn DK; Chwajol M; Mayer SA; Connolly ES
    Stroke; 2008 Sep; 39(9):2617-21. PubMed ID: 18658042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ε-Aminocaproic acid in angiographically negative subarachnoid hemorrhage patients is safe: a retrospective review of 83 consecutive patients.
    Hui FK; Schuette AJ; Lieber M; Spiotta AM; Moskowitz SI; Barrow DL; Cawley CM
    Neurosurgery; 2012 Mar; 70(3):702-5; discussion 705-6. PubMed ID: 21904257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epsilon amino caproic acid myopathy: additional features.
    Van Renterghem D; De Reuck J; Schelstraete K; Elinck W; Van der Straeten M
    Clin Neurol Neurosurg; 1984; 86(3):153-7. PubMed ID: 6091962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experimental epsilon-aminocaproic acid (EACA) administration in the presence of subarachnoid blood.
    Ewald T; Mahaley S; Goodrich J; Wilkinson R; Silver D
    J Neurosurg; 1971 Dec; 35(6):657-63. PubMed ID: 5171110
    [No Abstract]   [Full Text] [Related]  

  • 20. Allergic contact dermatitis from epsilon-aminocaproic acid.
    Shono M
    Contact Dermatitis; 1989 Aug; 21(2):106-7. PubMed ID: 2530047
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.